NCT06640491View on ClinicalTrials.gov

Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

December 1, 2030

Study Completion Date

December 1, 2035

Conditions
Total Knee Arthroplasty
Interventions
DRUG

IO Administration of Cefazolin

Intraosseous injection of cefazolin to guard against infection.

DRUG

IO Administration of Vancomycin

Intraosseous injection of vancomycin to guard against infection.

DRUG

IV Administration of Cefazolin

Intravenous dose of cefazolin to guard against infection.

DRUG

IV Administration of Vancomycin

Intravenous dose of vancomycin to guard against infection.

Trial Locations (1)

77030

RECRUITING

Houston Methodist Hospital, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER